Medicon Valley Alliance News

Medicon Valley Alliance Newshttp://www.mva.orgMVA Newsen-usmva@mva.orgThe MVA News Section Is Closed Until Mid-August 2010http://www.mva.org/composite-4217.htm 2010-07-09T00:00:004217SEED Capital Has Invested in 5 Life Science Companies in Q1-Q2 of 2010http://www.mva.org/composite-4215.htm 2010-07-08T00:00:004215Medicoindustrien Elects New Chairman of the Board (in Danish)http://www.mva.org/composite-4218.htm 2010-07-07T00:00:004218Nycomed’s Anti-Inflammatory Therapy Daxas® Receives Marketing Authorisation in the EUhttp://www.mva.org/composite-4214.htm 2010-07-06T00:00:004214LifeCycle Pharma Announces Positive Results of Phase 2 Clinical Trial in Kidney Patientshttp://www.mva.org/composite-4213.htm 2010-07-05T00:00:004213Comment from MVA in Børsen: Tailwind for Medicon Valley (in Danish)http://www.mva.org/composite-4209.htm 2010-06-30T00:00:004209ALK's Acquisition of the Largest Allergy Vaccine Company in The Netherlands Approvedhttp://www.mva.org/composite-4206.htm 2010-06-29T00:00:004206Business.dk: Danish Biotech is 15 Billion Short (in Danish)http://www.mva.org/composite-4204.htm 2010-06-28T00:00:004204New Data Demonstrate the Benefits of Victoza® (liraglutide)http://www.mva.org/composite-4205.htm 2010-06-26T00:00:004205Beyond Borders 2010: Danish Biotech Is Loosing Groundhttp://www.mva.org/composite-4220.htm 2010-06-24T00:00:004220Increasingly More Projects Are Tapped in Phase II (in Swedish)http://www.mva.org/composite-4201.htm 2010-06-24T00:00:004201Santaris Pharma A/S and miRagen Therapeutics, Inc. Form Strategic Alliancehttp://www.mva.org/composite-4199.htm 2010-06-23T00:00:004199AstraZeneca and Targacept Initiate Phase 3 Clinical Development of TC-5214http://www.mva.org/composite-4198.htm 2010-06-23T00:00:004198Novo Nordisk Re-Initiates Phase 3 Development of Liraglutide for Obesityhttp://www.mva.org/composite-4200.htm 2010-06-22T00:00:004200TV2/Lorry and Sydnytt: Medicon Valley - 10 Years After the Oresund Bridgehttp://www.mva.org/composite-4194.htm 2010-06-22T00:00:004194Exiqon Licenses Locked Nucleic Acids for Infectious Disease Diagnostics to BDhttp://www.mva.org/composite-4193.htm 2010-06-21T00:00:004193Three Billion to New Innovative Medicines Initiative Project (in Swedish)http://www.mva.org/composite-4192.htm 2010-06-18T00:00:004192Danish national radio: One-hour debate about attracting capital to Medicon Valley (in Danish)http://www.mva.org/composite-4190.htm 2010-06-18T00:00:004190Daniel Spasic of TFS Is This Year's Founder in Southern Sweden (in Swedish)http://www.mva.org/composite-4179.htm 2010-06-16T00:00:004179Genmab Announces Change in Managementhttp://www.mva.org/composite-4181.htm 2010-06-15T00:00:004181Genzyme’s Alemtuzumab for Treatment of Multiple Sclerosis Granted Fast Track Status by FDAhttp://www.mva.org/composite-4180.htm 2010-06-14T00:00:004180Chemel AB Appoints New CEO (in Swedish)http://www.mva.org/composite-4178.htm 2010-06-10T00:00:004178Virogates: Single Blood Test Can Predict Severe Diseases and Mortalityhttp://www.mva.org/composite-4175.htm 2010-06-10T00:00:004175Article in Nature: Spotlight on the Diverse Opportunities of Danish Life Sciencehttp://www.mva.org/composite-4172.htm 2010-06-10T00:00:004172Zealand Pharma Extends The Lixisenatide Global Licensing Agreement with sanofi-aventishttp://www.mva.org/composite-4170.htm 2010-06-10T00:00:004170Genzyme and Carl Icahn Reach Agreementhttp://www.mva.org/composite-4177.htm 2010-06-09T00:00:004177New Bio-chip Technology Will Prompt Cheaper and Faster Development of Medicinehttp://www.mva.org/composite-4176.htm 2010-06-09T00:00:004176Action Pharma Obtains Encouraging Preliminary Results in a Phase II Clinical Trial with AP214http://www.mva.org/composite-4174.htm 2010-06-09T00:00:004174Active Biotech's TASQ Prostate Cancer Project Presented at ASCOhttp://www.mva.org/composite-4166.htm 2010-06-07T00:00:004166Osaka University and Medicon Valley Alliance Engage in Strategic Partnershiphttp://www.mva.org/composite-4160.htm 2010-06-07T00:00:004160AstraZeneca Receives FDA Complete Response Letter for AXANUM New Drug Applicationhttp://www.mva.org/composite-4164.htm 2010-06-05T00:00:004164Ground-breaking Results Give Virogates New Prospects within Prognosishttp://www.mva.org/composite-4165.htm 2010-06-04T00:00:004165Novo Nordisk: Victoza® To Be Launched in Japan in June (2 June 2010)http://www.mva.org/composite-4153.htm 2010-06-02T00:00:004153Region Skåne Is Investing 75 million in Strategic Research (in Swedish)http://www.mva.org/composite-4152.htm 2010-06-02T00:00:004152Capital Intensive CROs and CMOs Act as Venture Capitalists (in Swedish)http://www.mva.org/composite-4147.htm 2010-05-28T00:00:004147Genzyme Receives FDA Approval for Lumizyme for Pompe Diseasehttp://www.mva.org/composite-4145.htm 2010-05-28T00:00:004145CellaVision Approved for IPO on NASDAQ OMX Stockholm (in Swedish)http://www.mva.org/composite-4141.htm 2010-05-28T00:00:004141Largest Individual Shareholder, Industrifonden, Sells Bioinvent Shares (in Swedish)http://www.mva.org/composite-4146.htm 2010-05-27T00:00:004146First Patients Recruited in the Extended Phase III Programme Using Lu AA21004 in MDDhttp://www.mva.org/composite-4144.htm 2010-05-27T00:00:004144BioInvent to Receive €10 Million Milestone for New Clinical Study with TB-403http://www.mva.org/composite-4132.htm 2010-05-17T00:00:004132Novo Nordisk Partners with International Scientific Community for Victoza®http://www.mva.org/composite-4133.htm 2010-05-10T00:00:004133Lund University Find Hormone to Predict Diabetes (in Swedish)http://www.mva.org/composite-4121.htm 2010-05-07T00:00:004121Danish Biotech under Pressure (in Danish)http://www.mva.org/composite-4119.htm 2010-05-04T00:00:004119GE Healthcare and Nycomed to Form Joint Venture for Medical Diagnostic Contrast Agentshttp://www.mva.org/composite-4113.htm 2010-05-03T00:00:004113Genovis Has Received SEK 1.4 million in Research Supporthttp://www.mva.org/composite-4114.htm 2010-05-03T00:00:004114Affitech Change in Ownershiphttp://www.mva.org/composite-4112.htm 2010-04-30T00:00:004112NeuroSearch A/S Announces the Results of Data from the Phase III MermaiHD Studyhttp://www.mva.org/composite-4111.htm 2010-04-30T00:00:004111Nycomed and Merck & Co., Inc., Announce Commercialisation Agreements for Daxas®http://www.mva.org/composite-4110.htm 2010-04-29T00:00:004110Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9http://www.mva.org/composite-4109.htm 2010-04-29T00:00:004109Kyoto University's iCeMS to Collaborate with Medicon Valleyhttp://www.mva.org/composite-4103.htm 2010-04-28T00:00:004103Lund University: Cancer Tumors that Fight Cancerhttp://www.mva.org/composite-4100.htm 2010-04-28T00:00:004100Symphogen Announces Publication in Molecular Biotechnology of Sympress™ II Production Systemhttp://www.mva.org/composite-4108.htm 2010-04-26T00:00:004108ALK Proposes to Acquire the Largest Allergy Vaccine Company in the Netherlandshttp://www.mva.org/composite-4107.htm 2010-04-26T00:00:004107Affitech Signs Strategic Alliance with Russian Biotech Partnerhttp://www.mva.org/composite-4104.htm 2010-04-25T00:00:004104Genmab Announces Pipeline and Technology Updatehttp://www.mva.org/composite-4105.htm 2010-04-24T00:00:004105The Lancet Publishes New Data Demonstrating the Superior Efficacy of Victoza® (liraglutide) Compared to Januvia® (sitagliptin)http://www.mva.org/composite-4106.htm 2010-04-23T00:00:004106Denmark to Get Back in Front (in Swedish)http://www.mva.org/composite-4097.htm 2010-04-21T00:00:004097BioInvent Focuses Manufacturing Operations on Proprietary Product Developmenthttp://www.mva.org/composite-4094.htm 2010-04-20T00:00:004094Evolva Reports Revenues Up 59% in 2009 - Funding Secured for Next 2-3 Yearshttp://www.mva.org/composite-4092.htm 2010-04-19T00:00:004092Active Biotech: New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of MShttp://www.mva.org/composite-4091.htm 2010-04-15T00:00:004091Positive Phase III Diabetes Data with Lixisenatide Announced by Zealandhttp://www.mva.org/composite-4090.htm 2010-04-15T00:00:004090Possible Public Take-Over of AstraZeneca Facililties in Lund (In Swedish)http://www.mva.org/composite-4088.htm 2010-04-14T00:00:004088More Clinical Trials to Denmark (In Danish)http://www.mva.org/composite-4085.htm 2010-04-12T00:00:004085The Danish Front Runners in Cancer Research (In Danish)http://www.mva.org/composite-4086.htm 2010-04-07T00:00:004086Ten New Biotech Companies i Denmark in 2009 (In Danish)http://www.mva.org/composite-4084.htm 2010-04-06T00:00:004084Nycomed and Baxter Receive FDA Approval for TachoSil®, An Adjunct to Haemostasis in Cardiovascular Surgeryhttp://www.mva.org/composite-4083.htm 2010-04-06T00:00:004083Novel Agent for Treatment of Parkinson's Disease - Lu AE04621 - Enters Lundbeck's Development Pipelinehttp://www.mva.org/composite-4082.htm 2010-04-06T00:00:004082TopoTarget Appoints Anders Fink Vadsholt As New CFO & Head of IRhttp://www.mva.org/composite-4081.htm 2010-04-01T00:00:004081LU: Folic Acid in Dietary Supplements Could Increase Risk of Breast Cancerhttp://www.mva.org/composite-4080.htm 2010-04-01T00:00:004080Active Biotech Raises SEK 149 Million through a Directed Share Issuehttp://www.mva.org/composite-4079.htm 2010-04-01T00:00:004079AstraZeneca and Abbott Receive FDA Complete Response Letter on CERTRIAD New Drug Applicationhttp://www.mva.org/composite-4076.htm 2010-04-01T00:00:004076Tomato Genes Produce Promising Results against Brain Tumourshttp://www.mva.org/composite-4077.htm 2010-04-01T00:00:004077Novozymes Launches New Bioinsecticide Made from Naturally-Occurring Soil Fungushttp://www.mva.org/composite-4078.htm 2010-04-01T00:00:004078Symphogen Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors in the UShttp://www.mva.org/composite-4075.htm 2010-04-01T00:00:004075Santaris Pharma A/S Forms Strategic Alliance to Develop RNA-based Medicineshttp://www.mva.org/composite-3881.htm 2009-11-23T00:00:003881Get Support in Handling Your Interreg IV A Applicationhttp://www.mva.org/composite-3901.htm 2009-09-28T00:00:003901Combine Bio Partnering Meeting and Great Skiing in Whistlerhttp://www.mva.org/composite-3902.htm 2009-09-28T00:00:003902Three New Ambassadors Joining the Life Science Ambassador Programmehttp://www.mva.org/composite-3894.htm 2009-09-28T00:00:003894Canada Joins The Life Science Ambassador Programmehttp://www.mva.org/composite-3900.htm 2009-09-28T00:00:003900Biomedical Educational Collaboration Across the Soundhttp://www.mva.org/composite-3896.htm 2009-09-28T00:00:003896Zealand Pharma Advances a New Generation of Type 2 Diabetes Treatmenthttp://www.mva.org/composite-3882.htm 2009-09-28T00:00:003882Medicon Valley Alliance's Annual Meeting 2009http://www.mva.org/composite-3897.htm 2009-09-28T00:00:003897Medicon Valley Cross-Border Award 2009http://www.mva.org/composite-3898.htm 2009-09-28T00:00:003898MVA Newsletter, September 2009http://www.mva.org/composite-3929.htm 2009-09-01T00:00:003929The News Section is Temporarely Closedhttp://www.mva.org/composite-3832.htm 2009-07-01T00:00:003832MVA Newsletter, June 2009http://www.mva.org/composite-3831.htm 2009-07-01T00:00:003831Clinical Trials Update: Lu AA24530 Shows Positive Results in Major Depressive Disorder Phase II Studyhttp://www.mva.org/composite-3327.htm 2009-06-30T00:00:003327Call for Proposals for 2011 ESF Research Conferenceshttp://www.mva.org/composite-3827.htm 2009-06-30T00:00:003827The Baltic Sea Region to Strengthen Smart Growthhttp://www.mva.org/composite-3826.htm 2009-06-29T00:00:003826NNE Pharmaplan Expands in Skånehttp://www.mva.org/composite-3844.htm 2009-06-23T00:00:003844Hansa Medical and Inverness Medical Innovations begin a Partnership Agreement (in Swedish)http://www.mva.org/composite-3821.htm 2009-06-22T00:00:003821LU Bioscience Invests in Novel Anti-Cancer Treatment Companyhttp://www.mva.org/composite-3815.htm 2009-06-19T00:00:003815Two of the Largest European Intellectuel Property Law Firms, Albihns and Zacco, Mergehttp://www.mva.org/composite-3814.htm 2009-06-18T00:00:003814Hansa Medical and Axis-Shield Enter Agreement on New Biomarker (in Swedish)http://www.mva.org/composite-3810.htm 2009-06-16T00:00:003810The Novo Nordisk Foundation Center for Protein Research Is Now Openhttp://www.mva.org/composite-3809.htm 2009-06-10T00:00:003809Novo Nordisk: The Lancet Publishes Direct Comparison Study Between Liraglutide And Exenatidehttp://www.mva.org/composite-3804.htm 2009-06-09T00:00:003804DTU Nanotech Receives DKK 28 Million in Donation (in Danish)http://www.mva.org/composite-3802.htm 2009-06-04T00:00:003802Rapidus Analysis of the Decision on ESS: Now the Work Begins (in Swedish)http://www.mva.org/composite-3801.htm 2009-06-03T00:00:003801High Spirit & Tough Competition at Medicon Valley Golf Championship 2009http://www.mva.org/composite-3820.htm 2009-06-02T00:00:003820New Alarm Device for Kidney Failure Patients Nominated for Prestigious Design Awardhttp://www.mva.org/composite-3800.htm 2009-06-02T00:00:003800